Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Peter Blume-JensenPresident and CEO | Acrivon TherapeuticsACRV | Open-market buy | 01/14 | 01/16 | 49,000 sh | $1.68 | $82,320 | +2.4% |
Kristina MassonEVP - Business Operations | Acrivon TherapeuticsACRV | Open-market buy | 01/14 | 01/16 | 49,000 sh | $1.68 | $82,320 | +2.4% |
Adam D. LevyCFO | Acrivon TherapeuticsACRV | Open-market buy | 01/14 | 01/16 | 8,832 sh | $1.70 | $15,014.4 | +72.7% |
Eric DevroeCOO | Acrivon TherapeuticsACRV | Open-market buy | 01/13 | 01/15 | 10,000 sh | $1.72 | $17,200 | +15.3% |
Acrivon TherapeuticsACRV | Open-market sale | 25/04/30–25/05/01 | 25/05/01 | 736,767 sh2 trades | $1.38avg. | $1,017,919.45 | −19.2% | |
Acrivon TherapeuticsACRV | Open-market sale | 25/04/30–25/05/01 | 25/05/01 | 736,767 sh2 trades | $1.38avg. | $1,017,919.45 | −19.2% | |
Acrivon TherapeuticsACRV | Open-market sale | 25/04/30–25/05/01 | 25/05/01 | 736,767 sh2 trades | $1.38avg. | $1,017,919.45 | −19.2% | |
Acrivon TherapeuticsACRV | Open-market sale | 25/04/25–25/04/29 | 25/04/29 | 1,519,952 sh3 trades | $1.81avg. | $2,744,946.03 | −28.4% | |
Acrivon TherapeuticsACRV | Open-market sale | 25/04/25–25/04/29 | 25/04/29 | 1,519,952 sh3 trades | $1.81avg. | $2,744,946.03 | −28.4% | |
Acrivon TherapeuticsACRV | Open-market sale | 25/04/25–25/04/29 | 25/04/29 | 1,519,952 sh3 trades | $1.81avg. | $2,744,946.03 | −28.4% | |
Joseph Edelman10% Owner | Acrivon TherapeuticsACRV | Open-market buy | 24/04/11 | 24/04/15 | 2,353,000 sh | $8.50 | $20,000,500 | +78.2% |
Perceptive Advisors10% Owner | Acrivon TherapeuticsACRV | Open-market buy | 24/04/11 | 24/04/15 | 2,353,000 sh | $8.50 | $20,000,500 | +78.2% |
Perceptive Life Sciences Master Fund10% Owner | Acrivon TherapeuticsACRV | Open-market buy | 24/04/11 | 24/04/15 | 2,353,000 sh | $8.50 | $20,000,500 | +78.2% |
Chione10% Owner | Acrivon TherapeuticsACRV | Open-market sale | 23/06/26 | 23/06/28 | 16 sh | $12.93 | $206.88 | −0.0% |
Andreas Hadjimichael10% Owner | Acrivon TherapeuticsACRV | Open-market sale | 23/06/26 | 23/06/28 | 16 sh | $12.93 | $206.88 | −0.0% |
Wiaczeslaw Smolokowski10% Owner | Acrivon TherapeuticsACRV | Open-market sale | 23/06/26 | 23/06/28 | 16 sh | $12.93 | $206.88 | −0.0% |
Marcin Czernik10% Owner | Acrivon TherapeuticsACRV | Open-market sale | 23/06/26 | 23/06/28 | 16 sh | $12.93 | $206.88 | −0.0% |
Anastasis Nikolaou10% Owner | Acrivon TherapeuticsACRV | Open-market sale | 23/06/26 | 23/06/28 | 16 sh | $12.93 | $206.88 | −0.0% |
Chione10% Owner | Acrivon TherapeuticsACRV | Open-market sale | 23/06/15 | 23/06/20 | 2,056 sh | $12.14 | $24,959.84 | −0.1% |
Andreas Hadjimichael10% Owner | Acrivon TherapeuticsACRV | Open-market sale | 23/06/15 | 23/06/20 | 2,056 sh | $12.14 | $24,959.84 | −0.1% |